You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Citation Tools

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Piha-Paul SA, Geva R, Tan TJ, et al
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Journal for ImmunoTherapy of Cancer 2021;9:e002863. doi: 10.1136/jitc-2021-002863